CABG plus surgical aortic valve replacement for treatment of coronary disease and aortic stenosis was associated with better 5-year outcomes vs. PCI plus transcatheter aortic valve replacement in ...
GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...
SGMC Health recently achieved the successful completion of its first transcarotid access Transcatheter Aortic Valve ...
Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...
We came across a bullish thesis on Edwards Lifesciences Corporation (EW) on Substack by Natan. In this article, we will ...
The global heart valve frame market is poised for significant growth over the coming years, driven by factors such as increasing prevalence of cardiovascular ...
Dr. Ron Aviles explains available procedures and recovery time for those with heart and vascular conditions. Sponsored by Overlake Medical Center and Clinics.
The US Food and Drugs Administration (FDA) is expected to approve the JenaValve Trilogy System, a transcatheter aortic valve ...
Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback